Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck

BACKGROUND: Recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is a common cancer with high recurrence and mortality. Current treatments have low response rates (RRs). METHODS: Fifty-three patients with R/M SCCHN received continuous oral buparlisib. In parallel, patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye Ryun, Kang, Han Na, Yun, Mi Ran, Ju, Kwon Young, Choi, Jae Woo, Jung, Dong Min, Pyo, Kyoung Ho, Hong, Min Hee, Ahn, Myoung-Ju, Sun, Jong-Mu, Kim, Han Sang, Kim, Jinna, Yoo, Jinseon, Kim, Kyu Ryung, Koh, Yoon Woo, Kim, Se Heon, Choi, Eun Chang, Yoon, Sun Ock, Shim, Hyo Sup, Paik, Soonmyung, Kim, Tae-Min, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722843/
https://www.ncbi.nlm.nih.gov/pubmed/32963347
http://dx.doi.org/10.1038/s41416-020-01074-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722843/
https://www.ncbi.nlm.nih.gov/pubmed/32963347
http://dx.doi.org/10.1038/s41416-020-01074-2

Ejemplares similares